Insmed, a biopharmaceutical specialist in rare diseases, is stealing the spotlight in 2025 with a stunning 62% gain, ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

A new analysis of nationally representative surveys from 56 mostly low- and middle-income countries (LMICs) showed that ...

Consumer discretionary stocks are at the forefront of the retail and leisure sectors, driven by robust consumer spending ...

Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS ...

Long Trade IdeaEnter your long position between 297.78 (yesterday's intra-day low) and 304.07 (yesterday's intra-day high).Market Index Analys ...

Cancer clinical trials in the UK are at a critical juncture. They face significant systemic pressures within the NHS and regulatory pathways that threaten efficiency and timeliness. Both commercial ...

Gene Therapy Market Gene therapy market surges on breakthroughs in genome editing, rising chronic & genetic disease cases, regulatory appro ...

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has ...

Wall Street expects a year-over-year decline in earnings on higher revenues when MannKind (MNKD) reports results for the ...